Stocks and Investing Stocks and Investing
Thu, March 2, 2023

Andrew Fein Reiterated (ZNTL) at Strong Buy and Held Target at $55 on, Mar 2nd, 2023


Published on 2024-10-28 02:03:11 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Zentalis Pharmaceuticals, Inc." (ZNTL) at Strong Buy and Held Target at $55 on, Mar 2nd, 2023.

Andrew has made no other calls on ZNTL in the last 4 months.



There are 6 other peers that have a rating on ZNTL. Out of the 6 peers that are also analyzing ZNTL, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Andrew


  • Bradley Canino of "Stifel" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, March 1st, 2023
  • Robert Driscoll of "Wedbush" Maintained at Buy with Decreased Target to $32 on, Monday, November 14th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $55 on, Friday, November 11th, 2022
  • Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Decreased Target to $28 on, Friday, November 11th, 2022
  • Matthew Biegler of "Oppenheimer" Maintained at Buy with Decreased Target to $50 on, Thursday, November 10th, 2022
  • Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $27 on, Thursday, November 10th, 2022
Contributing Sources